Tempus AI (NASDAQ:TEM) CEO Eric Lefkofsky Sells 166,250 Shares

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 166,250 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $57.48, for a total value of $9,556,050.00. Following the transaction, the chief executive officer directly owned 8,775,283 shares in the company, valued at approximately $504,403,266.84. This represents a 1.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Trading Up 6.3%

Shares of NASDAQ TEM traded up $3.67 during midday trading on Wednesday, hitting $61.60. The stock had a trading volume of 8,936,767 shares, compared to its average volume of 6,015,111. The firm has a market cap of $11.06 billion, a P/E ratio of -35.81 and a beta of 3.62. Tempus AI, Inc. has a fifty-two week low of $41.73 and a fifty-two week high of $104.32. The company has a debt-to-equity ratio of 2.96, a current ratio of 3.31 and a quick ratio of 3.15. The company’s 50-day simple moving average is $50.19 and its 200 day simple moving average is $54.68.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.08. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The firm had revenue of $348.12 million during the quarter, compared to analysts’ expectations of $345.44 million. During the same period in the previous year, the business posted ($0.24) EPS. The company’s quarterly revenue was up 36.1% compared to the same quarter last year. Research analysts anticipate that Tempus AI, Inc. will post -1.35 EPS for the current year.

Institutional Investors Weigh In On Tempus AI

Several hedge funds have recently bought and sold shares of the company. JPL Wealth Management LLC bought a new stake in shares of Tempus AI in the 3rd quarter valued at $26,000. Los Angeles Capital Management LLC bought a new position in Tempus AI during the fourth quarter worth about $27,000. Harvest Fund Management Co. Ltd bought a new position in Tempus AI during the third quarter worth about $38,000. Danske Bank A S acquired a new position in Tempus AI in the third quarter valued at about $48,000. Finally, Sunbelt Securities Inc. bought a new stake in shares of Tempus AI in the third quarter worth about $52,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have commented on TEM shares. HC Wainwright lowered their target price on shares of Tempus AI from $95.00 to $64.00 and set a “buy” rating for the company in a report on Monday, May 11th. TD Cowen raised their price target on Tempus AI from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tempus AI in a research note on Wednesday, June 17th. Guggenheim dropped their price objective on Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a report on Monday, March 30th. Finally, BTIG Research reissued a “buy” rating and issued a $80.00 target price on shares of Tempus AI in a research note on Monday, June 1st. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $68.54.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.